文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者接受端口递送系统或每月注射治疗后的渗出情况

Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections.
PubMed 文献 · Am J Ophthalmol · 2023-07-13

该研究回顾性分析Archway和Portal试验中44例接受端口递送系统(PDS)和32例接受每月注射的新生血管性年龄相关性黄斑变性患者的每次访视OCT扫描,评估黄斑中心凹渗出的存在、类型和严重程度。PDS植入后44眼中20眼(45%)从未出现中心凹渗出,15眼(34%)为轻度、3眼(7%)为中度、4眼(9%)为重度;渗出最常见为视网膜下液(50%)。结论认为PDS对中心凹渗出提供良好控制,渗出发生时通常消退且不影响视力。

要点

  • PDS植入后44眼中20眼(45%)从未出现中心凹渗出,15眼(34%)为轻度、3眼(7%)为中度、4眼(9%)为重度。
  • 渗出存在时最常见为视网膜下液(50%)。
  • PDS植入后中心凹中度或重度渗出的7眼中,5眼最终视力良好,2眼因黄斑下出血视力下降。

核心结论

  • PDS对新生血管性年龄相关性黄斑变性患者的中心凹渗出提供良好控制,渗出发生时通常消退且对视力无负面影响。

研究设计与样本

  • 回顾性分析前瞻性获取的数据,纳入Archway和Portal试验中44例PDS组和32例每月注射组患者,评估每次访视的频域OCT扫描。

主要发现

  • PDS植入后44眼中20眼(45%)从未出现中心凹渗出,2眼(5%)从未出现中心凹渗出但有数次访视缺失,15眼(34%)为轻度、3眼(7%)为中度、4眼(9%)为重度渗出(至少一次访视)。
  • 渗出存在时最常见为视网膜下液(50%)。
  • 随机分配至每月注射的32例患者中,15例(47%)在每月注射期间或PDS植入后中心凹无渗出。
  • 部分患者在PDS植入后或每月注射期间出现中心凹渗出随时间波动,对最佳矫正视力影响很小或无法识别。
  • PDS植入后中心凹中度或重度渗出的7眼中,5眼最终视力良好(3眼20/25,1眼20/40,1眼20/50),2眼因黄斑下出血视力下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate for the presence, severity, and type of exudation at each study visit for a subgroup of patients with neovascular age-related macular degeneration from the Archway and Portal trials. DESIGN: Retrospective analysis of prospectively obtained data. METHODS: Spectral-domain optical coherence tomography scans from each study visit of 44 patients from the Port Delivery System (PDS) arm and 32 patients from the monthly injection arm of Archway were evaluated, and composites of horizontal scans through the fovea were created. Each composite was graded for the presence, type, and severity of exudation and impact on best-corrected visual acuity. RESULTS: After PDS implantation, 20 of 44 eyes (45%) never showed any exudation in the fovea, 2 (5%) never showed exudation in the fovea but had several missed visits, whereas 15 (34%), 3 (7%), and 4 (9%) showed mild, moderate, or severe exudation at 1 or more study visits, respectively. When exudation was present, it was most commonly subretinal fluid (50%). Of 32 patients randomized to monthly injections, 15 (47%) had no exudation in the fovea during monthly injections or after PDS implantation. Fluctuation of exudation in the fovea over time was seen in some patients after PDS implantation or during monthly injections with little or no identifiable impact on best-corrected visual acuity. In the 7 eyes with moderate or severe exudation in the fovea after PDS implantation, final vision was good in 5 (20/25 in 3, 20/40 in 1, and 20/50 in 1) and 2 had reduced vision from submacular hemorrhage. CONCLUSIONS: The PDS provides excellent control of exudation in the fovea in patients with neovascular age-related macular degeneration, and when exudation occurs, it often resolves without a negative impact on vision.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Akhlaq A, Williams D, Clark WL, et al. Exudation in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System or Monthly Injections. Am J Ophthalmol. 2023. PMID: 37453472. doi:10.1016/j.ajo.2023.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。